← 返回

肿瘤相关巨噬细胞作为治疗靶点:解析相互作用网络并推进临床转化

英文原题:Tumor-Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation.

查看英文原题

Tumor-Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation.

PubMed 2026/01/28(内容时间) MedComm (2020) Q1 · IF 14.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤相关巨噬细胞(TAMs)是肿瘤微环境中含量最丰富的免疫细胞群体,也是恶性进展和治疗耐药的核心驱动因素。实体瘤中TAMs高浸润始终与不良临床结局相关,这主要归因于其在建立免疫抑制微环境中的作用,该微环境支持肿瘤生长、转移,并削弱化疗、放疗(RT)和免疫检查点抑制剂的疗效。尽管TAMs被公认为肿瘤进展的促进因素,但开发有效的治疗性靶向策略仍是未满足的临床需求。在本综述中,我们探讨了TAMs促进恶性肿瘤的多方面机制,包括吞噬信号调节、代谢重编程、外泌体通讯以及与其他免疫细胞的串扰。我们还评估了三种关键治疗策略:阻断TAMs的募集和存活、将TAMs重编程为抗肿瘤表型,以及新兴的嵌合抗原受体巨噬细胞疗法。此外,我们强调了将TAMs靶向策略与常规化疗、RT和免疫治疗方法整合的协同潜力。通过综合当前临床证据,本综述旨在为下一代TAMs靶向干预措施的合理设计提供信息,并提出克服治疗耐药的新策略。

展开英文摘要原文

Tumor-associated macrophages (TAMs) represent the most abundant immune cell population within the tumor microenvironment and are central drivers of malignant progression and treatment resistance. High TAMs infiltration in solid tumors consistently correlates with poor clinical outcomes, largely due to their role in establishing an immunosuppressive milieu that supports tumor growth, metastasis, and undermines the efficacy of chemotherapy, radiotherapy (RT), and immune checkpoint inhibitors.

Although TAMs are well-recognized promoters of tumor progression, the development of effective strategies to therapeutically target them remains an unmet clinical need. In this review, we examine the multifaceted mechanisms through which TAMs contribute to malignancy, including phagocytic signaling modulation, metabolic reprogramming, exosomal communication, and crosstalk with other immune cells.

We also evaluate three key therapeutic strategies: blocking TAMs recruitment and survival, reprogramming TAMs toward antitumor phenotypes, and the emerging approach of chimeric antigen receptor macrophage therapy.

Furthermore, we highlight the synergistic potential of integrating TAMs-targeted strategies with conventional chemotherapy, RT, and immunotherapeutic approaches. By synthesizing current clinical evidence, this review aims to inform the rational design of next-generation TAMs-targeted interventions and to propose novel strategies for overcoming treatment resistance.

论文信息

作者
Bao W、Qu X、Wang Y、Huang D、Zhang H、Dong M、Sun H、Yang Z
第一作者单位
School of Life Sciences Jilin University Changchun China.China
通讯作者单位
Cancer Center The First Hospital of Jilin University Changchun China.China
文献类型
综述
期刊
MedComm2026 Feb
原文标识
PubMed 41614207 · DOI 10.1002/mco2.70599